Odisha Approves Pharma & MedTech Policy to Build Sector Hubs & Boost Investment

The new policy will help Odisha build a competitive ecosystem for pharmaceutical and MedTech manufacturing, offering investors modern infrastructure, incentives and streamlined approvals to scale operations.

The Odisha Cabinet has approved a new Pharma & MedTech Policy designed to position the state as a competitive hub for pharmaceutical manufacturing, medical device production, and healthcare innovation.

The policy is expected to drive large-scale investment and accelerate the development of sector-specific industrial clusters equipped with advanced infrastructure and streamlined regulatory processes.

Announcing the approval, Chief Secretary Pradeep Kumar Jena said the new policy will give Odisha a stronger presence in India’s expanding healthcare manufacturing landscape. “The Pharma and MedTech sector have significant potential for growth,” he noted.

Adding that the policy aims to support investors with incentives, land availability and plug-and-play facilities to help companies scale faster.

The initiative includes the creation of dedicated industrial hubs to attract pharmaceutical companies, bulk drug manufacturers, diagnostic device producers and MedTech innovators.

Industries Secretary Hemant Sharma highlighted that the policy is designed to help Odisha tap into rising demand for domestic manufacturing. “We see this as an opportunity to build a reliable, high-quality ecosystem that supports both innovation and large-scale production,” he said.

By expanding manufacturing capacities within the state, Odisha aims to strengthen supply chains and provide a conducive environment for research, technology upgrades and global export opportunities.

The Cabinet also emphasized the policy’s potential to create high-skilled employment and foster industry-academia collaboration across pharmaceuticals and MedTech.

Hemant Sharma mentioned the state is prepared to offer investor-friendly support. “Our focus is on creating long-term value for companies and ensuring Odisha becomes a preferred destination for the life sciences sector.”

With the policy now in place, the government is expected to initiate development work within planned industrial zones and begin outreach to domestic and international manufacturers.

Related Posts

US FDA launches expedited IND Pilot, begins accepting applications

The US Food and Drug Administration (FDA) announced the final design of the Expedited Investigational New Drug (IND) Pilot. Accelerating clinical trial timelines and eliminating regulatory hurdles to maintain American…

PIL in SC seeks time-bound probe, stringent action against fake drug networks

The plea, filed by lawyer Ashwini Upadhyay, sought directions to the Centre and states to complete investigations into fake medicine cases within three months and trials within one year. New…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

US FDA launches expedited IND Pilot, begins accepting applications

US FDA launches expedited IND Pilot, begins accepting applications

PIL in SC seeks time-bound probe, stringent action against fake drug networks

PIL in SC seeks time-bound probe, stringent action against fake drug networks

Ghaziabad: Fake supplement racket busted, 5 held

Ghaziabad: Fake supplement racket busted, 5 held

22 medical stores raided in Hisar, 7 stocked dual-use drugs without records

22 medical stores raided in Hisar, 7 stocked dual-use drugs without records

Fake drug racket: Bengaluru healthcare firm owner held, SIT probes supply to hospitals, clinics

Fake drug racket: Bengaluru healthcare firm owner held, SIT probes supply to hospitals, clinics

Max Healthcare Foundation announces fourth edition of Max Medical Scholarship Programme

Max Healthcare Foundation announces fourth edition of Max Medical Scholarship Programme